This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
ARPP21 / cAMP-regulated phosphoprotein 21 · IHC design guide
Design Immunohistochemistry for ARPP21
Plan ARPP21 IHC in paraffin sections using the cytoplasmic tissue pattern reported for brain and skeletal muscle (HPA tissue IHC). Start with the catalog antibody’s 1:100–1:300 IHC dilution range (datasheet) and compare stained cells with an HPA-negative cell population (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
ARPP21 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic in brain and skeletal muscle (HPA tissue IHC) | |
| Staining pattern | Cytoplasmic brain staining; skeletal myocytes stain weakly (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Appendix+2 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A03525-1) | |
| Caveat | Brain staining varies by region and cell type (HPA tissue IHC) | |
| Regulation | Expression regulation is not specified (UniProt) | |
| Isoform / epitope | Six isoforms; epitope coverage is unknown (UniProt) |
Section 1
Recommended ARPP21 IHC & IF Protocols
The catalog antibody IHC-P protocol is followed by one published ARPP21 protocol using dual chromogenic staining of human spinal cord (PMC13545126).
| Sample | Paraffin-embedded human heart tissue; fixative not specified (datasheet A03525-1) |
| Fixation | Image fixative and duration unreported (datasheet A03525-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-ARPP21, 1:100-1:300 (datasheet A03525-1) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | ARPP21-positive staining in goblet cells of appendix (HPA tissue IHC: Medium). HPA tissue profile: Cytoplasmic expression in the brain and skeletal muscles. No signal in the no-primary control. |
💡Decision noteStart with citrate pH 6.0 retrieval at 95–98 °C for 20 min (page antigen retrieval; UniProt Q9UBL0: cytoplasm).
Section 2
What Is the Expected ARPP21 Staining Pattern?
In paraffin tissue sections, expect ARPP21 staining mainly in the cytoplasm of cerebral cortex neurons and caudate glial cells; appendix goblet cells also show signal (HPA tissue IHC: Medium in each). The tissue profile includes cytoplasmic expression in brain and skeletal muscle (HPA tissue IHC). ARPP21 is cytoplasmic and has no transmembrane segment (UniProt Q9UBL0). HPA rates the tissue IHC profile Enhanced, while reporting medium consistency between staining and RNA data (HPA tissue IHC).
| Cytoplasmic staining in cerebral cortex neurons or caudate glial cells. | This matches the reported compartment and cell types; HPA scores both cell populations Medium. Compare stained cells with adjacent tissue, rather than treating all cells in the section as equally positive (HPA tissue IHC). |
| Staining in appendix goblet cells. | A Medium goblet cell signal is also documented and can provide a second tissue context for interpretation (HPA tissue IHC). Its presence does not mean that every epithelial cell should stain. |
| Predominantly nuclear chromogen in a paraffin section, without the expected cytoplasmic pattern. | Treat this IHC result as questionable and review morphology and controls (HPA tissue IHC: cytoplasmic profile). HPA separately reports approved nucleolar plus cytosolic localisation by ICC-IF, so nuclear signal alone cannot establish an IHC artefact (HPA subcellular ICC-IF). |
| Strong signal in cells reported as undetected, such as adipose tissue adipocytes or adrenal gland glandular cells. | This conflicts with those HPA tissue IHC observations. Consider nonspecific antibody binding or endogenous detection activity, then check a reagent control before calling the cells ARPP21 positive (HPA tissue IHC: Not detected). |
| Diffuse chromogen across cells and extracellular areas, or no signal in the expected positive cells. | Diffuse deposit lacks the reported cell and compartment pattern; absent signal in cortex neurons or caudate glia makes a negative interpretation uncertain (HPA tissue IHC: Medium). Review controls, section quality and the general IHC detection workflow. |
💡Expected ARPP21 appearanceCall an IHC section positive when cytoplasmic signal of approximately the reported Medium level is discernible in cerebral cortex neurons, caudate glia or appendix goblet cells; broad diffuse deposit or strong staining in HPA-undetected cells is suspect (HPA tissue IHC).
| Tissue and cell selection | Brain RNA is tissue enriched, but protein staining differs by cell population: cortex neurons and caudate glia are Medium, cerebellar granular-layer cells are Not detected, and skeletal muscle myocytes are Low (HPA tissue IHC). Select controls at the cell level. |
| Antibody evidence | HPA017303 has Enhanced IHC validation (HPA antibodies). The overall tissue profile has Enhanced reliability with medium staining-to-RNA consistency (HPA tissue IHC); these ratings support comparison with the reported pattern, not a guarantee for every section. |
| Isoform context | UniProt lists 6 isoforms: isoform 2 is expressed in brain, while isoform 1 is present in immature thymocytes at protein level (UniProt Q9UBL0). The supplied evidence does not identify which isoform the IHC antibody detects, so staining cannot assign an isoform. |
| Topology and processing | ARPP21 has no transmembrane segment, signal peptide or propeptide; the annotated chain spans residues 2–812 (UniProt Q9UBL0). Interpret the reported IHC pattern as intracellular, without inferring surface staining or shedding from this record. |
| IF/ICC comparison: should its nucleolar pattern override tissue IHC? | No. ICC-IF reports approved nucleolar and additional cytosolic localisation in cultured cells (HPA subcellular ICC-IF), whereas tissue IHC reports cytoplasmic expression (HPA tissue IHC). Record the preparation and method when comparing results; this section does not establish an IF/ICC protocol. |
| Situation | Likely cause | Next action |
|---|---|---|
| No stain in cerebral cortex neurons or caudate glia. | The result conflicts with the reported Medium staining in those cells (HPA tissue IHC); a failed detection step or unsuitable section is also possible (general IHC practice). | Check a positive-control section, reagent order and chromogen development. Confirm that the intended cell population is present before interpreting the section as negative (general IHC practice). |
| Only nuclear staining appears in tissue IHC. | The distribution differs from HPA's cytoplasmic tissue profile; ICC-IF separately reports nucleolar localisation (HPA tissue IHC; HPA subcellular ICC-IF). | Review cell boundaries and counterstain, compare with the cytoplasmic positive-control pattern, and report the method-specific discrepancy rather than assigning a compartment from this slide alone. |
| Strong stain appears in adipocytes or adrenal gland glandular cells. | Those populations are reported Not detected (HPA tissue IHC). Nonspecific binding or endogenous detection activity may mimic signal (general IHC practice). | Compare with a control omitting primary antibody and, where applicable, an endogenous-activity control. Reassess staining only after checking those controls (general IHC practice). |
| Weak or patchy signal in skeletal muscle myocytes. | HPA reports Low staining in myocytes, so a faint result can reflect the documented pattern (HPA tissue IHC). | Judge signal against background and a stronger reported positive population, such as cortex neurons, before calling the muscle section failed (HPA tissue IHC: Medium in cortex neurons). |
| Diffuse background obscures cell boundaries. | Background deposit can prevent assessment of the expected cytoplasmic and cell-specific distribution (HPA tissue IHC: cytoplasmic profile; general IHC practice). | Check the no-primary control; review blocking, washing and detection reagent exposure as general IHC troubleshooting steps. Score localisation only where cell boundaries remain readable. |
| A cerebellar granular-layer section shows no signal. | HPA reports those cells as Not detected, despite Medium staining in other brain populations (HPA tissue IHC). | Use the intended cell population when judging the result. Include cortex neurons or caudate glia as a reported positive reference before concluding that detection failed (HPA tissue IHC). |
Experiment evidence
IHC & IF images showing ARPP21 staining
A03525-1 · IHCImmunohistochemistry analysis of paraffin-embedded human heart tissue, using ARPP21 Antibody. The picture on the right is blocked with the s
A30584 · IHCImmunohistochemistry analysis of paraffin-embedded human heart tissue, using ARPP21 Antibody. The picture on the right is blocked with the s
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000172995-ARPP21/tissue/cerebral+cortex#imid_17583478
HPA · CaudateHuman Protein Atlas IHC, Caudate. Source: https://www.proteinatlas.org/ENSG00000172995-ARPP21/tissue/basal+ganglia#imid_17583480
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000172995-ARPP21/tissue/colon#imid_17576009
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000172995-ARPP21/tissue/liver#imid_17576002
HPA · ICC-IF Rh30Human Protein Atlas immunofluorescence, Rh30, antibody HPA017303; green = ARPP21, blue = nucleus, red = microtubules.
HPA · ICC-IF Rh30Human Protein Atlas immunofluorescence, Rh30, antibody HPA017303; green = ARPP21, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for ARPP21 IHC & IF
🧪Run cerebral cortex first and score staining in neuronal cells, where HPA reports a Medium level (HPA: cerebral cortex, neuronal cells, Medium). Use adipose tissue as the negative tissue, assessing adipocytes reported as Not detected; on the cortex slide, use cells without specific staining as internal background comparators, without assuming every non-neuronal cell is negative (HPA: adipose tissue, adipocytes, Not detected; HPA: cerebral cortex, neuronal cells, Medium).
Positive control tissue: Appendix (Goblet cells, HPA Medium)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show ARPP21 in Rh30, U-251MG, U2OS, with annotated localisation: Nucleoli (approved) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control and a host- and clonality-matched isotype control; use a validated ARPP21 knockout sample or a peptide-blocked section as the target-specific control (standard IHC practice; selected A03525-1 tissue-IHC caption: peptide-blocked section). For cortex IHC, quench endogenous peroxidase and distinguish tissue pigment from chromogen when scoring (standard IHC practice).
⚠️Feasibility: The supplied evidence reports no ARPP21-specific fixation window or retrieval dependency, so optimize antigen retrieval on matched paraffin sections (supplied target/application evidence; standard IHC practice). The selected A03525-1 paraffin-section caption does not state a fixative; the supplied evidence does not establish whether frozen sections or IF are easier (selected A03525-1 tissue-IHC caption; supplied target/application evidence). In brain sections, neuronal lipofuscin can confound pigment assessment and autofluoresce, so check unstained controls if using IF (standard IHC/IF practice).
HPA tissue IHC evidence for ARPP21
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Appendix | Goblet cells | Medium | Protein (IHC) | HPA → |
| Caudate | Glial cells | Medium | Protein (IHC) | HPA → |
| Cerebral cortex | Neuronal cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced ARPP21 IHC Tips
Troubleshoot ARPP21 staining in paraffin sections by checking retrieval, cell type, compartment and controls before comparing chromogenic signal across samples.
What retrieval should I try first if ARPP21 staining is weak?
Start with citrate buffer at pH 6.0 for heat-induced retrieval at 95–98 °C for 20 min (page retrieval setting). If signal is weak, compare a shorter and longer heating time on matched sections while keeping detection and exposure to chromogen constant (standard IHC practice). Excessive heating can damage morphology or increase background, so judge staining alongside tissue preservation (standard IHC practice). Include a neuronal region of cerebral cortex as a positive comparison (HPA tissue IHC: medium staining in cerebral cortex neuronal cells). Score cytoplasmic signal separately from nuclear staining because the reported tissue profile is cytoplasmic (HPA tissue IHC).
Could fixation explain weak or patchy ARPP21 staining?
ARPP21-specific fixation sensitivity is unknown from the supplied evidence; the selected paraffin-section caption does not report a fixative (A03525-1 tissue-IHC caption). Record the fixative and fixation duration for each specimen before comparing staining intensity across blocks (standard IHC practice). If processing varies, stain matched positive-control sections in the same run and inspect morphology before changing antibody concentration (standard IHC practice; HPA tissue IHC: medium staining in cerebral cortex neuronal cells). Avoid assigning weak signal to phosphorylation or membrane accessibility on fixation grounds alone: phosphorylated residues and the absence of a transmembrane segment establish neither fixation effect (UniProt Q9UBL0: modified residues and topology).
Which cellular compartment should count as positive in ARPP21 tissue IHC?
For chromogenic tissue IHC, prioritise cytoplasmic staining in the appropriate cells when scoring ARPP21 (HPA tissue IHC: cytoplasmic expression in brain and skeletal muscles; UniProt Q9UBL0: cytoplasm). Medium staining in cerebral cortex neuronal cells and caudate glial cells provides cell-level comparison points (HPA tissue IHC). Nucleolar staining is reported in a separate subcellular ICC/IF dataset, with cytosol also observed there (HPA subcellular: approved nucleoli and cytosol). Document nuclear or nucleolar signal separately rather than counting it automatically as tissue-IHC positivity, since assay and cell context differ (HPA tissue IHC; HPA subcellular; standard IHC interpretation).
How might isoforms or epitope placement change the IHC result?
ARPP21 has 6 reported isoforms, so establish which sequence the antibody immunogen recognises before interpreting absent staining as absent protein (UniProt Q9UBL0: isoforms 1–6; standard IHC practice). Isoform 2 is expressed in brain, whereas isoform 1 is present in immature thymocytes at the protein level (UniProt Q9UBL0: tissue specificity). The record lists R3H residues 164–227, SUZ residues 228–300 and several modified residues, but supplies no antibody epitope coordinates (UniProt Q9UBL0: domains and modified residues; A03525-1 tissue-IHC caption). Keep epitope coverage and retrieval effects as separate questions until the immunogen sequence and tissue controls resolve them (standard IHC practice).
How should I adapt ARPP21 assessment to multiplex IF?
For a separate IF experiment, pair ARPP21 with a validated marker identifying the expected neuronal or glial population, then assess cellular overlap rather than colour alone (HPA tissue IHC: cerebral cortex neuronal cells and caudate glial cells; standard IF practice). Choose a fluorophore whose emission is distinguishable from the specimen’s measured autofluorescence and include single-colour and no-primary controls (standard IF practice). ARPP21 lacks a transmembrane segment and has reported cytosolic and nucleolar localisation, so permeabilise when probing an intracellular epitope and optimise its strength against morphology (UniProt Q9UBL0: topology and cytoplasm; HPA subcellular; standard IF practice). Confirm antibody performance in IF separately; the supplied selected-SKU image establishes paraffin-section IHC only (A03525-1 tissue-IHC caption).
What should I change when the chromogenic stain looks diffuse?
Inspect a no-primary control, the counterstain and unstained tissue before attributing diffuse colour to ARPP21 (standard IHC practice). Block endogenous peroxidase for an enzyme-based DAB workflow, then optimise protein blocking, antibody dilution and wash stringency one variable at a time (standard IHC practice). Use the selected antibody’s peptide-blocked paraffin-section image as specificity context, while recognising that its caption does not state a fixative (A03525-1 tissue-IHC caption). Compare the same compartments and cell types across sections: cytoplasmic neuronal or glial signal is supported in brain, whereas adipocytes in adipose tissue are reported as undetected (HPA tissue IHC).
How should I quantify ARPP21 across stained tissue sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define eligible cells and cytoplasmic positivity before scoring, using the same threshold and imaging settings for every section (HPA tissue IHC: cytoplasmic profile; standard IHC practice). For intensity-based comparisons, calculate an H-score from the percentage of cells at each staining level; alternatively report percentage positive cells or positive-cell density per mm² (standard IHC practice). Normalise counts to the number of eligible cells or analysed tissue area, and exclude folds, necrosis and section edges by a preset rule (standard IHC practice). Stratify neuronal and glial populations when relevant, since both have reported medium staining in different brain regions (HPA tissue IHC: cerebral cortex neuronal cells and caudate glial cells).
How can I distinguish true ARPP21 signal from an artefact?
A credible positive pattern should agree with cell identity and the cytoplasmic tissue-IHC profile, such as neuronal cells in cerebral cortex or glial cells in caudate (HPA tissue IHC). Treat isolated nuclear staining cautiously: nucleoli are supported by separate ICC/IF localisation data, while the supplied tissue-IHC profile is cytoplasmic (HPA subcellular; HPA tissue IHC). Compare with no-primary and peptide-blocked controls, and inspect section edges, necrotic areas and endogenous enzyme staining before assigning a positive score (standard IHC practice; A03525-1 tissue-IHC caption: peptide-blocked image). A negative result in one tissue is not universal absence, since reported staining varies by tissue and cell type (HPA tissue IHC).
Boster reagents
Best ARPP21 / cAMP-regulated phosphoprotein 21 IHC Antibodies
Both anti-ARPP21 antibodies list IHC and IF applications and human and mouse reactivity (catalog applications; catalog reactivity). Each has an IHC image of paraffin-embedded human heart tissue (catalog image captions).
Real IHC data
Anti-ARPP-21 Antibody
Cat # A03525-1
Real IHC data
Anti-ARPP21 Antibody
Cat # A30584
A03525-1 lists IHC and IF for human and mouse and has an IHC image of paraffin-embedded human heart tissue (catalog applications; catalog reactivity; A03525-1 image caption). A30584 lists IHC, IF and ICC for human and mouse and has its own IHC image of paraffin-embedded human heart tissue (catalog applications; catalog reactivity; A30584 image caption).
Which to pick: For tissue IHC, either SKU has a paraffin-section image and a listed dilution of 1:100–1:300 (A03525-1 image caption and datasheet; A30584 image caption and datasheet). For IF/ICC, choose A30584 if ICC matters: it lists both ICC and IF, while A03525-1 lists IF (catalog applications). For human and mouse work, either rabbit polyclonal lists both species; each IHC image documents human heart only, and neither caption reports the fixative (catalog host and reactivity; A03525-1 image caption; A30584 image caption).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q9UBL0 (ARP21_HUMAN, cAMP-regulated phosphoprotein 21).
- Human Protein Atlas. ARPP21 tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. ARPP21 subcellular location (ICC-IF): Mainly localized to the nucleoli. In addition localized to the cytosol..
- Human Protein Atlas. ARPP21 antibody validation summary (1 antibodies).
- Familial, neuropathological and cellular analysis identify ARPP21 as a major amyotrophic lateral sclerosis associated gene in French cohorts. Acta neuropathologica 2026 — PMC13545126.
- PubMed PMID:8120638 — UniProt-cited evidence.
- PubMed PMID:10931946 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for ARPP21 (cAMP-regulated phosphoprotein 21). Expected localisation Cytoplasmic in brain and skeletal muscle (HPA tissue IHC). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: A03525-1 at 1:100-1:300 (the product's own IHC validation image is shown). Controls (HPA): positive Appendix (Goblet cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human heart tissue; fixative not specified (datasheet A03525-1); 2. Fixation: Image fixative and duration unreported (datasheet A03525-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-ARPP21, 1:100-1:300 (datasheet A03525-1); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A03525-1); Caveat: Brain staining varies by region and cell type (HPA tissue IHC); Isoform / epitope: Six isoforms; epitope coverage is unknown (UniProt); Regulation: Expression regulation is not specified (UniProt). Evidence: UniProt Q9UBL0, HPA tissue IHC · Enhanced, HPA ICC-IF · Mainly localized to the nucleoli. In addition localized to the…, Datasheet A03525-1, PMC13545126. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/ARPP21/immunohistochemistry-ihc-guide.